Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen KRYSTEXXA (pegloticase by Year
KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — Worldwide product sales ($M) ($M)
Amgen KRYSTEXXA (pegloticase: $1,340M in FY2025, up 13.1% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,340 | +13.1% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 1,185 | +335.7% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 272 | – | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2024-02-14) ↗ |
Breakdown
What makes up KRYSTEXXA (pegloticase
- KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — U.S. product sales ($M)1,340 · FY2025
- KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — Rest of World (ROW) product sales ($M)0 · FY2025
- KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — Worldwide reported sales growth YoY (%)13.0% · FY2025
Cite this data
StockData. (2026). Amgen KRYSTEXXA (pegloticase ($M), annual FY2021–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-krystexxa-ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.